Trial | NCT00347165  Report issue

Title

Intravitreal Bevacizumab for Age-Related Macular Degeneration
Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    bevacizumab ...

  • Study Participants

    50
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined.

The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD
Study Started
Sep 30
2005
Study Completion
Sep 30
2006
Last Update
Jul 04
2006
Estimate

Drug bevacizumab intravitreal injection

Criteria 

Inclusion Criteria:

age >50 age related macular degeneration

Exclusion Criteria:

moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease
No Results Posted